ALT正常慢性乙肝中隐匿显著肝病理的无创检测:多中心研究
该多中心研究纳入ALT正常(≤40 U/L)的初治CHB患者(HBeAg阳性137例、阴性253例),以肝活检为参考标准,评估以CK18-M65为核心的生物标志物组合。
要点
- ALT正常HBeAg阳性CHB患者中45.2%存在显著肝病理。
- CK18-M65诊断显著肝病理AUC 0.934,敏感度85.5%、特异度88%。
- CK18-M65+ CK18-M30+ GP73组合AUC 0.942,优于LSM等无创指标。
核心结论
- 以CK18-M65为核心的无创模型有助于检测ALT正常HBeAg阳性CHB患者的隐匿显著肝病理并进行风险分层。
- 该模型可能避免不必要的肝活检并识别早期干预候选者,但仍需更大队列验证。
研究设计与样本
- 多中心研究,2013至2023年筛查3258例CHB,纳入137例HBeAg阳性和253例HBeAg阴性、ALT正常(≤40 U/L)的初治患者。
- 所有参与者接受肝活检(参考标准)及肝功能与新型生物标志物检测,包括CK18-M30、CK18-M65、GP73、IL-10和IL-2受体。
主要发现
- HBeAg阳性患者中45.2%存在显著肝病理(炎症分级和/或纤维化分期≥2)。
- 高CK18-M65水平与严重肝损伤风险增加>40倍相关(调整OR 40.64)。
关键数值与推荐
- 显著肝病理定义为炎症分级和/或纤维化分期≥2。
- ALT正常定义为≤40 U/L。
- 高CK18-M65水平与严重肝损伤风险的调整OR为40.64。
临床怎么用
- 对于ALT正常的HBeAg阳性CHB患者,可考虑检测以CK18-M65为核心的生物标志物组合以评估隐匿显著肝病理风险。
- 高CK18-M65水平提示严重肝损伤风险显著增加,可能需早期干预并避免不必要的肝活检。
- 在HBeAg阴性ALT正常患者中,该模型诊断性能较弱,临床应用需谨慎。
局限性
- 研究结论需在更大队列中验证。
- HBeAg阴性患者中生物标志物诊断性能较弱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals with chronic hepatitis B (CHB) may harbor occult yet significant liver pathology despite normal alanine aminotransferase (ALT) levels, representing a major diagnostic challenge. We aimed to identify and validate noninvasive biomarkers for detecting significant liver pathology among this population. METHODS: This multicenter study screened 3258 CHB cases from 2013 to 2023, enrolling 137 treatment-naive hepatitis B e antigen (HBeAg)-positive (HBeAg+) and 253 HBeAg-negative patients with CHB with normal ALT levels (≤40 U/L). All participants underwent liver biopsy (reference standard) and measurement of liver function and novel biomarkers (including cytokeratin 18 [CK18]-M30, CK18-M65, Golgi protein (GP73), interleukin 10, and interleukin 2 receptor). Significant liver pathology was defined as inflammation grade and/or fibrosis stage ≥2. Sixteen CK18-M65-centered biomarker combinations were evaluated using 8 machine learning algorithms with multicenter stratified validation. RESULTS: Significant liver pathology was observed in 45.2% of patients with HBeAg+ infection. CK18-M65, CK18-M30, and GP73 were strongly correlated with the severity of pathology (correlation with inflammation grade, r = 0.757, r = 0.688, and r = 0.453, respectively; P < .001), independent of ALT levels. CK18-M65 demonstrated optimal diagnostic performance (area under the curve, 0.934 [95% confidence interval, .896-.973]) with 85.5% sensitivity and 88% specificity, especially in those with low-normal ALT. High CK18-M65 levels conferred >40-fold increased risk of severe liver injury (adjusted odds ratio, 40.64). The optimal biomarker combination (CK18-M65 + CK18-M30 + GP73) achieved an area under the receiver operating characteristic curve of 0.942, significantly outperforming liver stiffness measurement (0.824), aspartate aminotransferase-to-platelet ratio index (0.783), and Fibrosis-4 score (0.745) (all P < .01), with enhanced clinical utility. HBeAg-negative patients with CHB showed significant pathology in 46%, but exhibited weaker diagnostic performance. CONCLUSIONS: CK18-M65-centered biomarker models suggest promising noninvasive tools for detecting occult liver pathology and risk stratification of ALT-normal HBeAg+ CHB infection, potentially avoiding unnecessary biopsies while identifying candidates for early intervention, nonetheless requiring validation in larger cohorts.
引用
- Li X, Shi M, Wang X, et al. Noninvasive Detection of Occult yet Significant Liver Pathology in Alanine Aminotransferase-Normal Chronic Hepatitis B: A Multicenter Study. J Infect Dis. 2026. PMID: 41165446. doi:10.1093/infdis/jiaf554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。